Schrodinger, INC Form 4 insider transactions

EVP & CFO of Schrodinger, Geoffrey Craig Porges, reports acquisition and disposal of common stock and stock options, including vesting of restricted stock units and sales to cover tax liabilities.

Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc., reports the acquisition of restricted stock units and stock options.

Ramy Farid, CEO of Schrodinger, Inc., was granted stock options and restricted stock units (RSUs) on March 3, 2025, according to a Form 4 filing with the SEC.

Chief Medical Officer Margaret Dugan reports the grant of stock options and restricted stock units in Schrodinger, Inc.

Jenny Herman, SVP & Controller of Schrodinger, Inc., reports the acquisition of restricted stock units and stock options.

Kenneth Patrick Lorton, EVP, CTO & COO, Software at Schrodinger, Inc., reports the acquisition of 50,000 stock options and 12,500 restricted stock units (RSUs) on March 3, 2025.

EVP, CLO & CPO of Schrodinger, Inc., Yvonne Tran, reports the acquisition of restricted stock units and stock options.

Robert Lorne Abel, EVP and Chief Scientific Officer at Schrodinger, Inc., reports the acquisition of stock options and restricted stock units.

EVP, CLO & CPO of Schrodinger, Inc., Yvonne Tran, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Robert Lorne Abel, EVP and Chief Scientific Officer at Schrodinger, Inc., sold 1,225 shares of common stock on February 10, 2025, to cover withholding tax liabilities related to vested restricted stock units.

Kenneth Patrick Lorton, EVP, CTO & COO, Software at Schrodinger, Inc., sold 985 shares of common stock on February 11, 2025, to cover withholding tax obligations.

Jenny Herman, SVP & Controller of Schrodinger, Inc., sold 859 shares of common stock on February 11, 2025, to cover withholding tax obligations related to vesting restricted stock units.

Yvonne Tran, EVP, CLO & CPO of Schrodinger, Inc., sold 828 shares of common stock on February 11, 2025, to cover withholding tax liabilities related to vesting restricted stock units.

Margaret Dugan, Chief Medical Officer of Schrodinger, Inc., sold 1,531 shares of common stock on October 15, 2024, to cover withholding tax liabilities related to vesting restricted stock units.

Director Jeffrey Chodakewitz acquired 5,000 restricted stock units and stock options for 8,550 shares of Schrodinger, Inc. on June 18, 2024.

Director Rosana Kapeller-Libermann acquired stock options and restricted stock units in Schrodinger, Inc. on June 18, 2024.

Director Michael Lynton reported the acquisition of restricted stock units and stock options in Schrodinger, Inc.

Director Arun Oberoi reports the acquisition of restricted stock units and stock options in Schrodinger, Inc.

Director Gary Sender reports the acquisition of stock and option awards in Schrodinger, Inc.

Director Nancy Thornberry reported the grant of restricted stock units and stock options in Schrodinger, Inc.

Director Richard Friesner reports acquisition of Schrodinger shares and options through restricted stock units and a stock option grant.

Director Gary Ginsberg reported the acquisition of restricted stock units and stock options in Schrodinger, Inc.

Robert Lorne Abel, EVP and Chief Scientific Officer at Schrodinger, Inc., reported the grant of stock options on March 21, 2024.

Kenneth Patrick Lorton, EVP, CTO & COO, Software at Schrodinger, Inc., reported the acquisition of stock options on March 21, 2024.

Kenneth Patrick Lorton, EVP, CTO & COO, Software at Schrodinger, Inc., exercised stock options and reported changes in beneficial ownership on March 6, 2024.

EVP & CFO of Schrodinger, Geoffrey Craig Porges, reports acquisition of shares through vesting of performance-based restricted stock units and subsequent sale to cover tax obligations.

Ramy Farid, CEO of Schrodinger, Inc., reports the acquisition of stock options on March 4, 2024.

Jenny Herman, SVP & Controller of Schrodinger, Inc., reports the grant of restricted stock units and stock options.

Kenneth Patrick Lorton, EVP, CTO & COO, Software at Schrodinger, Inc., acquired 60,000 stock options on March 4, 2024, according to a Form 4 filing with the SEC.

Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc., reported the grant of stock options for 120,000 shares on March 4, 2024.